Clinical Trials

The following information is based on United States guidelines. Please check with your country’s requirements and regulations. To find Clinical Trials from The European Medical Agency go to https://www.clinicaltrialsregister.eu/

If you have questions regarding clinical trials, please contact us.

In a clinical trial, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or changes to participants’ behavior, such as diet. Clinical trials may compare a new medical approach to a standard one that is already available, to a placebo that contains no active ingredients, or to no intervention. Some clinical trials compare interventions that are already available to each other. When a new product or approach is being studied, it is not usually known whether it will be helpful, harmful, or no different than available alternatives (including no intervention). The investigators try to determine the safety and efficacy of the intervention by measuring certain outcomes in the participants. For example, investigators may give a drug or treatment to participants who have high blood pressure to see whether their blood pressure decreases.

Looking for information about clinical trials to give to your patients? Check out our Clinical Trial Information patient page.

Current Clinical Trials

The following clinical trials are automatically generated from ClinicalTrials.gov

Pemphigus

  • A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
    Conditions:   Age-Related Macular Degeneration;   Allergies;   Alpha-Gal Syndrome;   Alzheimer Disease;   Amyloidosis;   Ankylosing Spondylitis;   Arthritis;   Alopecia Areata;   Asthma;   Atopic Dermatitis;   Autism;   Autoimmune Hepatitis;   Behcet's Disease;   Beta-Thalassemia;   Cancer;   Celiac Disease;   Kidney Diseases;   COPD;   Crohn Disease;   Cystic Fibrosis;   Diabetes;   Dravet Syndrome;   DMD;   Fibromyalgia;   Graves Disease;   Thyroid Diseases;   Hepatitis;   Hidradenitis Suppurativa;   ITP;   Leukemia;   ALS;   Lupus or SLE;   Lymphoma;   Multiple Sclerosis;   Myasthenia Gravis;   Heart Diseases;   Parkinson Disease;   Pemphigus Vulgaris;   Cirrhosis;   Psoriasis;   Schizophrenia;   Scleroderma;   Sickle Cell Disease;   Stroke;   Ulcerative Colitis;   Vasculitis;   VitiligoIntervention:   Diagnostic Test: Specimen sampleSponsor:   Sanguine BiosciencesRecruiting
  • Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid
    Conditions:   Pemphigus Vulgaris;   Bullous PemphigoidInterventions:   Drug: Ozonated olive oil;   Drug: Topical garamycin creamSponsor:   Cairo UniversityRecruiting
  • Validation of 5-Point Investigator Global Assessments for Pemphigus
    Condition:   PemphigusIntervention:   Other: Investigator Global Assessments (IGAs)Sponsor:   Premier Specialists, AustraliaRecruiting
  • A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)
    Condition:   Pemphigus VulgarisInterventions:   Drug: Abatacept Prefilled Syringe;   Drug: Mycophenolate Mofetil 500Mg TabSponsors:   Tongji Hospital;   Wuhan Central Hospital;   Wuhan Hospital of Traditional Chinese MedicineRecruiting
  • Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
    Conditions:   Pemphigus;   Bullous Pemphigoid;   Stevens-Johnson Syndrome;   Toxic Epidermal NecrolysesIntervention:   Genetic: A single blood sample for HLA typingSponsors:   Sechenov University;   Pirogov Russian National Research Medical UniversityRecruiting
  • COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
    Conditions:   Rheumatoid Arthritis (RA);   Systemic Lupus Erythematosus (SLE);   Pemphigus Vulgaris;   Multiple Sclerosis (MS);   Systemic Sclerosis (SSc);   Pediatric SLE;   Juvenile Idiopathic Arthritis (JIA);   Juvenile Dermatomyositis (JDM);   Pediatric-Onset Multiple Sclerosis (POMS)Interventions:   Biological: Moderna mRNA-1273;   Biological: BNT162b2;   Biological: Ad26.COV2.S;   Drug: Continue IS (MMF or MPA);   Drug: Continue IS (MTX);   Biological: Continue IS (B cell depletion therapy);   Biological: Monovalent [B.1.351] CoV2 preS dTM-AS03;   Drug: Withhold IS (MMF or MPA);   Drug: Withhold IS (MTX);   Drug: Withhold IS (B cell depletion therapy);   Biological: Moderna mRNA-1273, Bivalent;   Biological: BNT162b2, BivalentSponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Autoimmunity Centers of Excellence;   Rho Federal Systems Division, Inc.Recruiting
  • Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
    Conditions:   Relapsing Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple SclerosisInterventions:   Drug: Rituximab;   Drug: Ocrelizumab;   Drug: Fexofenadine;   Drug: Paracetamol;   Drug: MethylprednisoloneSponsors:   Rigshospitalet, Denmark;   Odense University Hospital;   Aarhus University Hospital;   Aalborg University Hospital;   Herlev Hospital;   Hillerod Hospital, Denmark;   Zealand University Hospital;   Kolding Sygehus;   Regional Hospital Holstebro;   Hvidovre University Hospital;   Hospital of South West Jutland, Esbjerg, Denmark;   GCP unit, Copenhagen University Hospital;   GCP-unit at Aarhus University Hospital, Aarhus, Denmark;   Hospital of Southern Jutland, Sønderborg, Denmark;   Hospital of Central Denmark Region, Viborg, Denmark;   Danske RegionerRecruiting
  • A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
    Conditions:   Pemphigus Vulgaris;   Pemphigus FoliaceusInterventions:   Biological: efgartigimod PH20 SC;   Drug: prednisoneSponsor:   argenxRecruiting
  • A Prospective & Retrospective Study on Ectopic Lymphoid-like Structures in Chronic Skins of Autoimmune Bullous Diseases
    Condition:   Autoimmune Bullous DiseaseIntervention:   Procedure: BiopsySponsor:   Gangnam Severance HospitalRecruiting
  • Open-label Study to Determine the Maximum Tolerated Dose of DSG3-CAART in Mucosal-dominant PV Patients (mPV)
    Condition:   Mucosal -Dominant Pemphigus VulgarisIntervention:   Biological: DSG3-CAARTSponsor:   Cabaletta BioRecruiting

Pemphigoid

What are Pemphigus and Pemphigoid
Patients
Healthcare Professionals